Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Sees Large Growth in Short Interest

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 43,100 shares, a growth of 498.6% from the February 13th total of 7,200 shares. Based on an average daily volume of 196,400 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are short sold.

Chugai Pharmaceutical Trading Down 1.5 %

Shares of OTCMKTS:CHGCY traded down $0.35 on Friday, reaching $23.21. 577,516 shares of the company’s stock were exchanged, compared to its average volume of 201,717. Chugai Pharmaceutical has a twelve month low of $14.52 and a twelve month high of $27.19. The company has a fifty day moving average of $22.79 and a 200-day moving average of $22.99. The company has a market capitalization of $76.38 billion, a price-to-earnings ratio of 30.14 and a beta of 0.77.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.18 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. As a group, equities research analysts forecast that Chugai Pharmaceutical will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.